<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="13a89699-1829-4bb2-9adb-bea5ba52409b"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">RESTASIS</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">MULTIDOSE</content>
      <content styleCode="bold"> safely and effectively. See full prescribing information for </content>
      <content styleCode="bold">RESTASIS</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">MULTIDOSE</content>
      <content styleCode="bold">.</content>
      <br/>
      <content styleCode="bold"> </content>
      <br/>
      <content styleCode="bold">RESTASIS</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">MULTIDOSE</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">(</content>
      <content styleCode="bold">cyclosporine ophthalmic emulsion</content>
      <content styleCode="bold">) </content>
      <content styleCode="bold">0.05%</content>
      <content styleCode="bold">,</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">f</content>
      <content styleCode="bold">or topical ophthalmic use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: </content>
      <content styleCode="bold">1983</content>
      <br/>
   </title>
   <effectiveTime value="20250314"/>
   <setId root="7224d810-bb96-4682-a942-3355e6e8061a"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="144796497" root="1.3.6.1.4.1.519.1"/>
            <name>Allergan, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="50d10824-078f-46f4-93df-811da586b961"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250310"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0023-5301" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Restasis MultiDose</name>
                        <formCode code="C42913" displayName="EMULSION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cyclosporine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOSPORINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOSPORINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D5340Y2I9G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CASTOR OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="71DD5V995L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER COPOLYMER TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-5301-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20161110"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-5301-08" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20161110"/>
                                          <high value="20191231"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050790" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20161110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="1e7b49bd-c439-47a9-b809-85c173c9e0c2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
		     
	<content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">RESTASIS</content> <content styleCode="bold">MULTIDOSE</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> </content>ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">RESTASIS</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">MULTIDOSE</content> is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="2ff7e954-1119-40af-93fb-a2ba01c5627e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
		     
	<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>Instill one drop of <content styleCode="bold">RESTASIS</content> <content styleCode="bold">MULTIDOSE</content> ophthalmic emulsion twice a day in each eye approximately 12 hours apart. <content styleCode="bold">RESTASIS</content> <content styleCode="bold">MULTIDOSE</content> can be used concomitantly with lubricant eye drops, allowing a 15-minute interval between products.</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Prime by squeezing two drops onto a tissue before initial use. (<linkHtml href="#_2_1_Preparation_for">2.1</linkHtml>)<br/>
                           </item>
                           <item>Instill one drop of <content styleCode="bold">RESTASIS</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">MULTIDOSE</content> ophthalmic emulsion twice a day in each eye approximately 12 hours apart. (<linkHtml href="#_2_2_Preparation_for">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>Pull off the clear shipping cover by pulling straight up. Throw the shipping cover away. Do not use RESTASIS MULTIDOSETM if shipping cover or pull tab are damaged or missing.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Remove the pull tab on the olive green colored protective cap by pulling the end of the pull tab away from the bottle then winding it counterclockwise.  Throw away the pull tab.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Remove the olive green colored protective cap by pulling it straight up.  Keep the colored protective cap.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>Prime the bottle for first-time use by squeezing two drops onto a tissue.  Do not let the bottle tip touch the tissue.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000005">
                     <text>The bottle is now ready for use.  After use, recap the bottle with the olive green colored protective cap by pushing it straight down onto the bottle.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000006">
                     <text>Turn the bottle upside down a few times before giving your dose to make sure the medicine is mixed well.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="_2_1_Preparation_for">
                     <id root="db80be66-9d43-4f19-843e-3cd4d4a63d22"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1</content>
		     
	<content styleCode="bold">Preparation for First-Time Use</content>
                     </title>
                     <text>
                        <paragraph>Step 1: Pull off the clear shipping cover by pulling straight up. Throw the shipping cover away. Do not use <content styleCode="bold">RESTASIS MULTIDOSE</content> if shipping cover or pull tab are damaged or missing.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000001"/>
                        </paragraph>
                        <paragraph>Step 2: Remove the pull tab on the olive green colored protective cap by pulling the end of the pull tab away from the bottle then winding it counterclockwise.  Throw away the pull tab.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000002"/>
                        </paragraph>
                        <paragraph>Step 3: Remove the olive green colored protective cap by pulling it straight up.  Keep the colored protective cap.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000003"/>
                        </paragraph>
                        <paragraph>Step 4: Prime the bottle for first-time use by squeezing two drops onto a tissue.  Do not let the bottle tip touch the tissue.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000004"/>
                        </paragraph>
                        <paragraph>Step 5: The bottle is now ready for use.  After use, recap the bottle with the olive green colored protective cap by pushing it straight down onto the bottle.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000005"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Preparation_for">
                     <id root="fa2f02a0-7d73-4e3f-9fb8-25e2985c0eac"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2</content>
		     
	<content styleCode="bold">Preparation for Use</content>
                     </title>
                     <text>
                        <paragraph>Step 6: Turn the bottle upside down a few times before giving your dose to make sure the medicine is mixed well.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM03000006"/>
                        </paragraph>
                        <paragraph>Step 7: Instill one drop in the affected eye.  Replace the olive green colored protective cap.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_Dosage_Forms">
               <id root="b20ae31d-0167-48d1-8c94-5b0899f22684"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
		     
	<content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Ophthalmic emulsion containing cyclosporine 0.05% (0.5 mg/mL)</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cyclosporine ophthalmic emulsion 0.05%  (0.5 mg/mL) (<linkHtml href="#_3_Dosage_Forms">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_Contraindications">
               <id root="0c041e1b-081a-462d-8149-ae1c2773496f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
		     
	<content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">RESTASIS</content> <content styleCode="bold">MULTIDOSE</content> is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation <content styleCode="italics">[</content>
                     <content styleCode="italics">see </content>
                     <content styleCode="italics">
                        <linkHtml href="#_6_2_Post_marketing_Experience">Adverse Reactions (6.2)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>.</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity (<linkHtml href="#_4_Contraindications">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="2ff96c7f-5338-4384-b05b-b4994f3ea2f1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>To avoid the potential for eye injury and contamination, be careful not to touch the bottle tip to your eye or other surfaces. (<linkHtml href="#_5_1_Potential_for">5.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Potential_for">
                     <id root="2a4281c2-3851-42b4-8b27-0b62ab91ed87"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">1</content>
		     
	<content styleCode="bold">Potential for Eye Injury and Contamination</content>
                     </title>
                     <text>
                        <paragraph>Be careful not to touch the bottle tip to your eye or other surfaces to avoid potential for eye injury and contamination.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Use_with">
                     <id root="e1190b89-1be5-45b0-9411-00021690025b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2</content>
		     
	<content styleCode="bold">Use with Contact Lenses</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">RESTASIS MULTIDOSE </content>should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of <content styleCode="bold">RESTASIS MULTIDOSE </content>ophthalmic emulsion.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="afdd606e-575d-473d-ba7c-0867df5009a9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
		     
	<content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Potential for Eye Injury and Contamination <content styleCode="italics">[</content>
                        <content styleCode="italics">see </content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_1_Potential_for">Warnings and Precautions (5.1)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (17%). (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="03b06761-f2bb-4d40-9ea6-eb73c1d2b7d8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
		     
	<content styleCode="bold">Clinical </content>
                        <content styleCode="bold">Trials</content>
                        <content styleCode="bold"> Experience </content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion, 0.05% was ocular burning (17%).</paragraph>
                        <paragraph>Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="_6_2_Post_marketing_Experience">
                     <id root="17299a09-bb6e-496d-94d6-46b3bbf6ad60"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
		     
	<content styleCode="bold">Post-marketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of cyclosporine ophthalmic emulsion, 0.05%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>Reported reactions have included: hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea); and superficial injury of the eye (from the bottle tip touching the eye during administration). </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="790f6cef-6d36-49cb-8432-c9de9ee62429"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
		     
	<content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250314"/>
               <component>
                  <section>
                     <id root="cff2077a-ae2d-4869-be1f-4a2f8306cc25"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
		     
	<content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Clinical administration of cyclosporine ophthalmic emulsion 0.05% is not detected systemically following topical ocular administration <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>, and maternal use is not expected to result in fetal exposure to the drug. Oral administration of cyclosporine to pregnant rats or rabbits did not produce teratogenicity at clinically relevant doses <content styleCode="italics">[see Data]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/>At maternally toxic doses (30 mg/kg/day in rats and 100 mg/kg/day in rabbits), cyclosporine oral solution (USP) was teratogenic as indicated by increased pre- and postnatal mortality, reduced fetal weight and skeletal retardations. These doses (normalized to body surface area) are 5,000 and 32,000 times greater, respectively, than the daily recommended human dose of one drop (approximately 28 mcL) of cyclosporine ophthalmic emulsion 0.05%  twice daily into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. No evidence of embryofetal toxicity was observed in rats or rabbits receiving cyclosporine during organogenesis at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively. These doses in rats and rabbits are approximately 3,000 and 10,000 times greater, respectively, than the daily recommended human dose.</paragraph>
                        <paragraph>An oral dose of 45 mg/kg/day cyclosporine administered to rats from Day 15 of pregnancy until Day 21 postpartum produced maternal toxicity and an increase in postnatal mortality in offspring. This dose is 7,000 times greater than the daily recommended human dose. No adverse effects in dams or offspring were observed at oral doses up to 15 mg/kg/day (2,000 times greater than the daily recommended human dose).</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f732117a-e700-4824-b10c-141637adbb29"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2</content>
		     
	<content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Cyclosporine is known to appear in human milk following systemic administration, but its presence in human milk following topical treatment has not been investigated. Although blood concentrations are undetectable following topical administration of cyclosporine ophthalmic emulsion 0.05% <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>, caution should be exercised when <content styleCode="bold">RESTASIS</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">MULTIDOSE</content> is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for <content styleCode="bold">RESTASIS</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">MULTIDOSE</content> and any potential adverse effects on the breast-fed child from cyclosporine.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ab0c782b-0451-4e34-bd02-7cb48717f184"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
		     
	<content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and efficacy have not been established in pediatric patients below the age of 16.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9eb2b8a8-7a56-40a9-ba22-12b3e5b61a04"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
		     
	<content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>No overall difference in safety or effectiveness has been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="39dbeec0-951b-4623-8c6a-8e3447278817"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
		     
	<content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">RESTASIS</content>
                     <content styleCode="bold"> MULTIDOSE</content> (cyclosporine ophthalmic emulsion) 0.05% contains a calcineurin inhibitor immunosuppressant with anti-inflammatory effects. Cyclosporine’s chemical name is Cyclo[[(<content styleCode="italics">E</content>)-(2<content styleCode="italics">S</content>,3<content styleCode="italics">R</content>,4<content styleCode="italics">R</content>)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-<content styleCode="italics">N</content>-methylglycyl-<content styleCode="italics">N</content>-methyl-L-leucyl-L-valyl-<content styleCode="italics">N</content>-methyl-L-leucyl-L-alanyl-D-alanyl-<content styleCode="italics">N</content>-methyl-L-leucyl-<content styleCode="italics">N</content>-methyl-L-leucyl-<content styleCode="italics">N</content>-methyl-L-valyl] and it has the following structure:</paragraph>
                  <paragraph>Structural Formula</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000007"/>
                  </paragraph>
                  <paragraph>Formula: C<sub>62</sub>H<sub>111</sub>N<sub>11</sub>O<sub>12        </sub>Mol. Wt.: 1202.6</paragraph>
                  <paragraph>Cyclosporine is a fine white powder. <content styleCode="bold">RESTASIS</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">MULTIDOSE</content> appears as a white opaque to slightly translucent homogeneous emulsion. It has an osmolality of 230 to 320 mOsmol/kg and a pH of 6.5-8.0. Each mL of <content styleCode="bold">RESTASIS</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">MULTIDOSE</content> ophthalmic emulsion contains: <content styleCode="bold">Active:</content> cyclosporine 0.05%. <content styleCode="bold">Inactives:</content> glycerin; castor oil; polysorbate 80; carbomer copolymer type A; purified water; and sodium hydroxide to adjust pH.</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="MM03000007">
                     <text>The following structure formula for RESTASIS MULTIDOSETM is (cyclosporine ophthalmic emulsion) 0.05% contains a calcineurin inhibitor immunosuppressant with anti-inflammatory effects. Cyclosporine’s chemical name is Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl] </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1da24537-f6d6-4893-8c66-1bfa2675efe0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
		     
	<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250314"/>
               <component>
                  <section>
                     <id root="810497c3-5a63-4d8f-83bc-510f25bb8693"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
		     
	<content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Cyclosporine is an immunosuppressive agent when administered systemically.</paragraph>
                        <paragraph>In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, cyclosporine emulsion is thought to act as a partial immunomodulator. The exact mechanism of action is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="4b18fbc2-411b-46e7-8c8a-2636efe20471"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
		     
	<content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Blood cyclosporine A concentrations were measured using a specific high pressure liquid chromatography-mass spectrometry assay. Blood concentrations of cyclosporine, in all the samples collected, after topical administration of cyclosporine ophthalmic emulsion, 0.05%, twice daily, in humans for up to 12 months, were below the quantitation limit of 0.1 ng/mL. There was no detectable drug accumulation in blood during 12 months of treatment with cyclosporine ophthalmic emulsion, 0.05%.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="85f4ae60-172e-4b69-9d0f-130ae9aa9641"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
		     
	<content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250314"/>
               <component>
                  <section>
                     <id root="10228c1a-8fe9-4dc4-85b1-a9c2ac97fdd0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
		     
	<content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content> <br/>Systemic carcinogenicity studies were conducted in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value.</paragraph>
                        <paragraph>In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 80 times greater (normalized to body surface area) than the daily recommended human dose of one drop (approximately 28 mcL) of cyclosporine ophthalmic emulsion, 0.05% twice daily into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content> <br/>Cyclosporine has not been found to be mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes <content styleCode="italics">in vitro</content> gave indication of a positive effect (i.e., induction of SCE).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content> <br/>No impairment in fertility was demonstrated in studies in male and female rats receiving oral doses of cyclosporine up to 15 mg/kg/day (approximately 2,000 times the human daily dose of 0.001 mg/kg/day normalized to body surface area) for 9 weeks (male) and 2 weeks (female) prior to mating.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2f4c532d-0b52-4308-929f-9a93a5b000e2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
		     
	<content styleCode="bold">CLINICAL STUDIES</content>
                  <content styleCode="bold"> </content>
               </title>
               <text>
                  <paragraph>Four multicenter, randomized, adequate and well-controlled clinical studies were performed in approximately 1,200 patients with moderate to severe keratoconjunctivitis sicca. Cyclosporine ophthalmic emulsion, 0.05% demonstrated statistically significant increases in Schirmer wetting of 10 mm versus vehicle at six months in patients whose tear production was presumed to be suppressed due to ocular inflammation. This effect was seen in approximately 15% of cyclosporine ophthalmic emulsion, 0.05%-treated patients versus approximately 5% of vehicle-treated patients. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.</paragraph>
                  <paragraph>No increase in bacterial or fungal ocular infections was reported following administration of cyclosporine ophthalmic emulsion, 0.05%.</paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section>
               <id root="35da19ba-7d8a-4fa9-884b-a1a2927c0e28"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
		     
	<content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">RESTASIS</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">MULTIDOSE</content> ophthalmic emulsion is packaged in a sterile, multi-dose  bottle. Each bottle consists of a white opaque LDPE bottle, a white opaque polypropylene top with unidirectional valve and air filter, a protective olive green polypropylene cap, and a clear disposable shipping cover over the colored cap. RESTASIS MULTIDOSE contains no preservatives. </paragraph>
                  <paragraph>5.5 mL in 10-mL bottle - NDC 0023-5301-05</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>  Store at 15°C  to 25°C (59°F to 77°F).  After opening, RESTASIS MULTIDOSE can be used until the expiration date on the bottle. </paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section>
               <id root="808a5800-06a2-4a5b-86d6-8b71c667a624"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
		     
	<content styleCode="bold">PATIENT COUNSELING INFORMATION </content>
                  <br/>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#IFU">Instructions for Use</linkHtml>). <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Handling the Container</content>
                  </paragraph>
                  <paragraph>Advise patients to not allow the tip of the bottle to touch the eye or any surface, as this may contaminate the emulsion. Advise patients to not touch the bottle tip to their eye to avoid the potential for injury to the eye [<content styleCode="italics">see </content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Potential_for">Warnings and Precautions (5.1)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Use with Contact Lens</content>
                     <content styleCode="bold">es</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">RESTASIS </content>
                     <content styleCode="bold">MULTIDOSE </content>should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. Advise patients that if contact lenses are worn, they should be removed prior to the administration of the  emulsion. Lenses  may  be  reinserted 15 minutes following administration of  <content styleCode="bold">RESTASIS  </content>
                     <content styleCode="bold">MULTIDOSE  </content>ophthalmic  emulsion [<content styleCode="italics">see </content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Use_with">Warnings and Precautions (5.2)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Administration</content>
                  </paragraph>
                  <paragraph>Advise patients to read the “Instructions for Use” for detailed first-time use instructions.</paragraph>
                  <paragraph>Distributed by:<br/>AbbVie Inc. <br/>North Chicago, IL 60064</paragraph>
                  <paragraph>© 2025 AbbVie. All rights reserved.<br/>
                     <br/>RESTASIS MULTIDOSE and its design are trademarks of Allergan, Inc., an AbbVie company.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000008"/>
                  </paragraph>
                  <paragraph>v2.0USPI5301</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000009"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="MM03000008">
                     <text>Abbvie Logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000009">
                     <text>Cut here</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="895c7b66-1fa3-4189-8fb0-683adf33ed59"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                     <br/>
                     <content styleCode="bold">RESTASIS </content>
                     <content styleCode="bold">MULTIDOSE</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> (</content>
                     <content styleCode="bold">Re stay’ sis Mul tee dōs</content>
                     <content styleCode="bold">)</content>
                     <br/>
                     <content styleCode="bold">(</content>
                     <content styleCode="bold">cyclosporine </content>
                     <content styleCode="bold">ophthalmic emulsion</content>
                     <content styleCode="bold">)</content>
                     <content styleCode="bold"> 0.05%</content>
                  </paragraph>
                  <paragraph>Read this Instructions for Use before you start using <content styleCode="bold">RESTASIS MULTIDOSE</content> and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">RESTASIS MULTIDOSE</content> is for use in the eye<br/>
                     </item>
                     <item>Wash your hands before using <content styleCode="bold">RESTASIS MULTIDOSE</content>.<br/>
                     </item>
                     <item>Do not let the bottle tip touch the eye or any other surfaces to avoid contamination or injury to your eye.<br/>
                     </item>
                     <item>Use 1 drop of <content styleCode="bold">RESTASIS MULTIDOSE</content> in each eye, 2 times each day, about 12 hours apart.  <br/>
                     </item>
                     <item>If you wear contact lenses, remove them before using <content styleCode="bold">RESTASIS MULTIDOSE</content>.  Wait for at least 15 minutes before placing them back in your eyes.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">RESTASIS MULTIDOSE</content> can be used with lubricant eye drops, but you should wait at least 15 minutes between using each product.</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0300000A"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PREPARING THE BOTTLE  FOR FIRST-TIME USE</content>
                     <content styleCode="bold">:</content>
		     
	</paragraph>
                  <table>
                     <col width="444"/>
                     <col width="194"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 1:</content>   Pull off shipping cover by pulling straight up. Throw the shipping cover away.  <content styleCode="bold">Do not</content> use <content styleCode="bold">RESTASIS MULTIDOSE</content> if shipping cover or pull tab are damaged or missing.<br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM0300000B"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 2:</content>    Remove the pull tab on the olive green colored protective cap by pulling the end of the pull tab away from the bottle then winding it counterclockwise.  Throw away the pull tab.<br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM0300000C"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 3:</content>   Remove the olive green colored protective cap by pulling it straight up. Keep the colored protective cap.<br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM0300000D"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 4:</content>   Prime the bottle for first time use by squeezing 2 drops onto a tissue. Do not let the bottle tip touch the tissue.<br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM0300000E"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 5:</content>   The bottle is now ready for use. After use, recap the bottle with the olive green colored protective cap by pushing straight down onto the bottle.<br/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM0300000F"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">GIVING YOUR DOSE:</content> </paragraph>
                  <table>
                     <col width="444"/>
                     <col width="194"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 6:</content> Turn the bottle upside down a few times before giving your dose to make sure the medicine is mixed well. </td>
                           <td>
                              <renderMultiMedia referencedObject="MM03000010"/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 7: </content>Instill one drop in the affected eye. Replace the olive green colored protective cap.<content styleCode="bold"> </content>
                              <br/>
                           </td>
                           <td/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">How do I store RESTASIS MULTIDOSE?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store <content styleCode="bold">RESTASIS MULTIDOSE</content> between 15°C to 25°C (59°F to 77°F).<br/>
                     </item>
                     <item>After opening, <content styleCode="bold">RESTA</content>
                        <content styleCode="bold">S</content>
                        <content styleCode="bold">IS MULTIDOSE</content> can be used until the expiration date (EXP) on the bottle. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep</content> <content styleCode="bold">RESTASIS MULTIDOSE and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This Instructions for Use has been approved by the Food and Drug Administration. </paragraph>
                  <paragraph>Distributed by:<br/>AbbVie Inc. <br/>North Chicago, IL 60064</paragraph>
                  <paragraph>© 2025 AbbVie. All rights reserved.<br/>RESTASIS MULTIDOSE and its design are trademarks of Allergan, Inc., an AbbVie company.      </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000008"/>
                  </paragraph>
                  <paragraph>Approved: 3/2025<br/>v2.0IFU5301</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="MM0300000A">
                     <text>Parts of your Restatis Multidose bottle</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-0a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000B">
                     <text>Step 1:   Pull off shipping cover by pulling straight up. Throw the shipping cover away.  Do not use RESTASIS MULTIDOSETM if shipping cover or  pull tab are damaged or missing.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-0b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000C">
                     <text>Step 2:    Remove the pull tab on the olive green colored protective cap by pulling the end of the pull tab away from the bottle then winding it counterclockwise.  Throw away the pull tab.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-0c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000D">
                     <text>Step 3:   Remove the olive green colored protective cap by pulling it straight up. Keep the colored protective cap.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-0d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000E">
                     <text>Step 4:   Prime the bottle for first time use by squeezing 2 drops onto a tissue. Do not let the bottle tip touch the tissue.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-0e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000F">
                     <text>Step 5:   The bottle is now ready for use. After use, recap the bottle with the olive green colored protective cap by pushing straight down onto the bottle.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-0f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000010">
                     <text>Step 6: Turn the bottle upside down a few times before giving your dose to make sure the medicine is mixed well. </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="475533d6-2ab3-4fa5-bade-8f656d7136d5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <content styleCode="bold"> – Restasis Multidose Carton Label</content>
                  </paragraph>
                  <paragraph>NDC 0023-5301-05<br/>
                     <content styleCode="bold">abbvie</content>
                     <br/>
                     <content styleCode="bold italics">Restasis</content>
                     <content styleCode="bold italics">
                        <br/>MultiDose</content>
                     <content styleCode="bold">™</content>
                     <br/>
                     <content styleCode="italics">(Cyclosporine Ophthalmic Emulsion) 0.05%</content>
                     <br/>
                     <content styleCode="bold">For Topical Application </content>
                     <br/>
                     <content styleCode="bold">In the Eye</content>
                     <br/>
                     <content styleCode="italics">PRIOR TO FIRST USE, PLEASE READ </content>
                     <br/>
                     <content styleCode="italics">BOTTLE PREPARATION INSTRUCTIONS</content>
                     <br/>Sterile<content styleCode="bold">, </content>
                     <content styleCode="bold">5.5 mL</content>
                     <br/>Preservative-Free<content styleCode="bold"> </content>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000011"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="MM02000011">
                     <text>NDC 0023-5301-05
abbvie
Restasis
MultiDose™
(Cyclosporine Ophthalmic Emulsion) 0.05%
For Topical Application 
In the Eye
PRIOR TO FIRST USE, PLEASE READ 
BOTTLE PREPARATION INSTRUCTIONS
Sterile, 5.5 mL
Preservative-Free Rx Only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="restasis-multidose-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>